GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (LSE:OBD) » Definitions » EV-to-Revenue

Oxford BioDynamics (LSE:OBD) EV-to-Revenue : 51.86 (As of Apr. 29, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oxford BioDynamics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oxford BioDynamics's enterprise value is £26.45 Mil. Oxford BioDynamics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was £0.51 Mil. Therefore, Oxford BioDynamics's EV-to-Revenue for today is 51.86.

The historical rank and industry rank for Oxford BioDynamics's EV-to-Revenue or its related term are showing as below:

LSE:OBD' s EV-to-Revenue Range Over the Past 10 Years
Min: 25.75   Med: 104.77   Max: 272.9
Current: 51.86

During the past 11 years, the highest EV-to-Revenue of Oxford BioDynamics was 272.90. The lowest was 25.75. And the median was 104.77.

LSE:OBD's EV-to-Revenue is ranked worse than
79.01% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs LSE:OBD: 51.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Oxford BioDynamics's stock price is £0.081. Oxford BioDynamics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was £0.00. Therefore, Oxford BioDynamics's PS Ratio for today is 20.25.


Oxford BioDynamics EV-to-Revenue Historical Data

The historical data trend for Oxford BioDynamics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics EV-to-Revenue Chart

Oxford BioDynamics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.52 183.04 126.76 108.30 149.10

Oxford BioDynamics Semi-Annual Data
Sep13 Sep14 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 126.76 - 108.30 - 149.10

Competitive Comparison of Oxford BioDynamics's EV-to-Revenue

For the Biotechnology subindustry, Oxford BioDynamics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's EV-to-Revenue falls into.



Oxford BioDynamics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oxford BioDynamics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=26.449/0.51
=51.86

Oxford BioDynamics's current Enterprise Value is £26.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioDynamics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was £0.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioDynamics  (LSE:OBD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oxford BioDynamics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.081/0.004
=20.25

Oxford BioDynamics's share price for today is £0.081.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was £0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioDynamics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioDynamics (LSE:OBD) Business Description

Traded in Other Exchanges
Address
Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.

Oxford BioDynamics (LSE:OBD) Headlines

No Headlines